FDA Acceptance of Supplemental NDA for MS CONTIN by KNOA PHARMA
The FDA has accepted a supplemental NDA for MS CONTIN, containing morphine sulfate, submitted by KNOA PHARMA.
Therapeutic Area
Therapeutic area intelligence for Opioids with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.